Philly’s IntegriChain drug payment analytics firm, backed by Silicon Valley cash, buys another rival

IntegriChain, a Center City- and Ambler-based medical data analytics firm that employs 160, says it is acquiring Somerset, N.J.-based DaVIZta, an 80-person firm which focuses on healthcare payment data and analytics.

The combination collect prescription use and payment information so drug companies can project prices and profits. IntegriChain says its clients include Pfizer, Merck, Novartis, GlaxoSmithKline and other big drug companies. daVIZta serves Shire, Bausch Health and Amneal, among others.

“DaVIZta is a leading provider of revenue analytics software, including gross-to-net automation and government pricing solutions,” IntegriChain chief executive and cofounder Kevin Leininger said in a statement. The company plans to add daVIZta’s products into IntegriChain’s own ICyte program, Leininger added.

IntegriChain CEO Leininger and IntegriChain CFO Darren Weiss will keep those responsibilities at the expanded company. DaVIZta cofounder Shekhar Yerramilli said he and business partner Krishnan Padmanabhan will also stay with the firm.

This is IntegriChain’s third merger since Silicon Valley-based Accel-KKR bought out the firm’s non-management investors and began financing its speeded-up growth in 2016.

The companies aren’t saying what IntegriChain and its investors paid for DaVIZta.